Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Equillium Inc
(NQ:
EQ
)
1.720
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Equillium Inc
< Previous
1
2
3
Next >
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
Today 8:00 EDT
From
Equillium, Inc.
Via
Business Wire
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2024
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
April 01, 2024
From
Equillium, Inc.
Via
Business Wire
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
March 25, 2024
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
March 22, 2024
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease
December 21, 2023
From
Equillium, Inc.
Via
Business Wire
Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology
November 13, 2023
From
Equillium, Inc.
Via
Business Wire
Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
November 08, 2023
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
November 06, 2023
From
Equillium, Inc.
Via
Business Wire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
October 23, 2023
Via
ACCESSWIRE
Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology
October 19, 2023
From
Equillium
Via
Business Wire
Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium
October 16, 2023
From
Equillium Inc.
Via
Business Wire
Equillium to Host Analyst & Investor Day
October 03, 2023
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the JonesTrading 2023 Healthcare Summit
October 02, 2023
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences
September 20, 2023
From
Equillium, Inc.
Via
Business Wire
Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference
August 30, 2023
From
Equillium, Inc.
Via
Business Wire
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
August 09, 2023
From
Equillium, Inc.
Via
Business Wire
Equillium Announces $7.5 Million Share Repurchase Program
August 02, 2023
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences
June 01, 2023
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
May 15, 2023
From
Equillium, Inc.
Via
Business Wire
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
May 11, 2023
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation
April 24, 2023
From
Equillium, Inc.
Via
Business Wire
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates
March 23, 2023
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference
March 22, 2023
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR
February 17, 2023
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the SVB Securities Annual Global Healthcare Conference
February 07, 2023
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
January 13, 2023
From
Equillium, Inc.
Via
Business Wire
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement
December 23, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis
December 16, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
December 06, 2022
From
Equillium, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.